(Q33949316)

30 July 2017

title

Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects (English)

1 reference

30 July 2017

1 reference

30 July 2017

D Montefiori

1 reference

30 July 2017

G M Ortiz

1 reference

30 July 2017

M Wellons

1 reference

30 July 2017

J Brancato

1 reference

30 July 2017

H T Vo

1 reference

30 July 2017

R L Zinn

1 reference

30 July 2017

D E Clarkson

1 reference

30 July 2017

K Van Loon

1 reference

30 July 2017

G D Miralles

1 reference

30 July 2017

J A Bartlett

1 reference

30 July 2017

D F Nixon

1 reference

30 July 2017

language of work or name

English

0 references

publication date

30 October 2001

1 reference

Proceedings of the National Academy of Sciences of the United States of America

30 July 2017

published in

1 reference

30 July 2017

1 reference

30 July 2017

1 reference

30 July 2017

page(s)

13288-13293

1 reference

Sex differences in nevirapine rash

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=60863

Putative immunodominant human immunodeficiency virus-specific CD8(+) T-cell responses cannot be predicted by major histocompatibility complex class I haplotype

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=60863

Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=60863

Dynamics of HIV-specific CD8+ T lymphocytes with changes in viral load.The RESTIM and COMET Study Groups

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=60863

Anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiency

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=60863

Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=60863

HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=60863

HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=60863

Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=60863

Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=60863

Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=60863

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=60863

Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=60863

Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=60863

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=60863

Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=60863

Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA

28 July 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.221452198

Changes in Frequency of HIV‐1–Specific Cytotoxic T Cell Precursors and Circulating Effectors after Combination Antiretroviral Therapy in Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.221452198

Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.221452198

Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.221452198

Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.221452198

Control of HIV despite the Discontinuation of Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.221452198

Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.221452198

Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.221452198

Immune control of HIV-1 after early treatment of acute infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.221452198

Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.221452198

Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.221452198

HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.221452198

Rapid quantification of SIV-specific CD8 T cell responses with recombinant vaccinia virus ELISPOT or cytokine flow cytometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.221452198

Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.221452198

Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.221452198

Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1073%2FPNAS.221452198

Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=60863

Current approaches to treatment for HIV-1 infection.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=60863

Rebound of HIV-1 viral load after suppression to very low levels

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=60863

Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=60863

Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression

29 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/11687611

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/11687611

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/11687611

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1073/PNAS.221452198

1 reference

30 July 2017

0 references

1 reference

30 July 2017

1 reference